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Molecular Imaging and the Failing Heart
Through the Looking Glass*
Douglas L. Mann, MD, FACC
Houston, Texas“The time has come,” the Walrus said, “to talk of many
things: Of shoes—and ships and sealing wax—and
cabbages and kings, and why the sea is boiling hot—
and whether pigs have wings.”
—Lewis Carroll, Through the Looking Glass
and What Alice Found There (1871) (1)
Despite the many strides in the management of
heart failure during the past 2 decades, the efficacy
of our current pharmacologic approach in heart
failure is variable and is often unpredictable. Ac-
cordingly, there is growing need to develop person-
alized strategies for managing patients with heart
failure. Although pharmacogenomics has been pro-
posed as an important way to personalize heart
failure therapy (2), it does not allow for optimiza-
tion of drug dosage in individual patients. There
See page 187
has been growing interest in using molecular imag-
ing for phenotypic characterization of the failing
heart (reviewed in Jaffer and Weissleder [3]). In this
issue of the iJACC, van den Borne et al. (4) report
on the use of a novel arginine-glutamate-aspartate
(RGD) peptide, technetium-99m-labeled Cy5.5-
RGD-imaging peptide (CRIP) (5), to evaluate
changes in collagen synthesis in mice that were
treated with angiotensin and/or aldosterone antag-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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this paper.onists, either alone and in combination, after acute
coronary artery ligation. CRIP is a cyclic peptide
that was originally developed to image integrins
such as v3/5, which are up-regulated during
angiogenesis. Subsequently, CRIP was shown to
bind to integrins expressed in activated myofibro-
blasts as well as to correlate with new collagen
synthesis within the infarct zone (5). In the study in
this issue of iJACC, CRIP was intravenously ad-
ministered after 4 weeks after acute coronary occlu-
sion in mice that were treated with a single neuro-
hormonal antagonist (captopril, losartan, and
spironolactone) or with combinations of neurohor-
monal antagonists. At the time of terminal study
the hearts were characterized histopathologically for
the presence of myofibroblasts and for thick and
thin collagen fiber deposition with the use of
picrosirius red staining. The authors found that
CRIP uptake was maximal in the infarct zone of
untreated mice (2.3  0.14%) and was significantly
decreased in the animals that were treated with a
single neurohormonal antagonist (1.7  0.35%; p
 0.0002). Importantly, the addition of 2 neuro-
hormonal antagonists together (captopril  losar-
tan, spironolactone captopril or spironolactone
losartan) or all 3 neurohormonal antagonists (cap-
topril  losartan  spironolactone) further reduced
the uptake of 99mTc-labeled CRIP in the infarct
zone (1.31 0.40%; p 0.0001 and 1.16 0.26%;
p  0.0001, respectively). Importantly, the deposi-
tion of thin collagen fibers was significantly reduced
in mice treated with the neurohormonal antagonists
and was correlated with CRIP uptake. The authors
conclude that molecular imaging with CRIP allows
for the evaluation of the efficacy of neurohormonal
antagonists. To place the study in proper perspec-
tive, it is helpful to digress for a moment and discuss
what is known about the regulation of the extracel-
lular matrix in the failing human heart.
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200lterations in the Extracellular Matrix in the
ailing Heart
he cardiac fibroblast, which comprises the vast
ajority (90%) of nonmyocyte cells in the heart,
s the primary cell type that is responsible for the
ecretion of the majority of extracellular compo-
ents in the heart, such as collagens I, III, and IV;
aminin; and fibronectin. In response to mechanical
tress and/or neurohormonal activation (e.g., angio-
ensin and/or aldosterone), a subset of fibroblasts
ndergo phenotypic conversion to myofibroblasts,
hat are characterized by increased expression of
lpha-smooth muscle actin and enhanced secretory
ctivity. Myofibroblasts also express increased levels
f angiotensin receptors (6) and increased expres-
ion of v3/5 integrins, which function as receptors
or transforming growth factor 1, an extremely
rofibrotic peptide (7). Myofibroblasts migrate into
he area surrounding tissue injury, where they are
esponsible for the collagen secretion and contrac-
ion/realignment of the nascent collagen fibers and
hus play an important role in the final scar forma-
ion at the site of injury. Thus, increased activation
f myofibroblasts and increased collagen synthesis
re believed to contribute to disease progression in
eart failure. And indeed, studies in failing human
yocardium have shown that there is a quantitative
ncrease in collagen I, III, IV, and VI; fibronectin;
aminin; and vimentin (8) and that the ratio of type
collagen to type III collagen is decreased in
atients with ischemic cardiomyopathy (9). The
ccumulation of collagen, can occur on a “reactive”
asis around intramural coronary arteries and arte-
ioles (perivascular fibrosis) or in the interstitial
pace (interstitial fibrosis) and does not require
yocyte cell death.
Alternatively collagen accumulation can occur as
result of microscopic scarring (replacement fibro-
is), which develops in response to cardiac myocyte
ell loss. This scarring or “replacement fibrosis” is
n adaptation to the loss of parenchyma and is
herefore critical to preserve the structural integrity
f the heart. Indeed, the prevention of fibrosis
mmediately after infarction (i.e., disruption of
ound healing) has been associated with untoward
linical outcomes in clinical trials (10). However,
he increase in structural integrity that is provided
y increased collagen synthesis/accumulation comes
t a cost. That is, the increased fibrous tissue leads
o increased myocardial stiffness, which would pre-
umably result in decreased myocardial shortening
or a given degree of afterload. In addition, myo- sardial fibrosis may provide the structural substrate
or atrial and ventricular arrhythmias, thus poten-
ially contributing to sudden death. Accordingly,
he ability to monitor both the development of
yocardial fibrosis, as well as the total amount of
ollagen deposition in individual patients after an
cute myocardial infarction and/or in the failing
eart, would represent a significant positive step
oward individualizing heart failure therapy and
ould therefore be of significant clinical importance.
Although myocardial fibrosis (i.e., collagen
ontent) can be detected by late gadolinium-
nhancement and cardiac magnetic resonance im-
ging (11), our ability to monitor ongoing de novo
ollagen synthesis in the failing heart is limited to
onitoring circulating levels of fragments of colla-
en propeptides (e.g., N-terminal peptide collagen
ropeptides and C-terminal peptides) (12). How-
ver, although these circulating levels of these
iomarkers decrease in heart failure patients that
ave been treated with neurohormonal antagonists
13), these biomarkers are nonspecific insofar as
hey reflect ongoing collagen synthesis in the body
e.g., bone turnover), and may therefore have lim-
ted applicability in terms of guiding heart failure
herapies. Thus, the current study may be important
linically because it would allow for direct monitor-
ng of ongoing collagen synthesis in patients after
n acute myocardial infarction. This in turn would
llow for optimization of pharmacological ap-
roaches for these patients.
However, there are 2 potential limitations of this
ovel imaging approach that warrant further dis-
ussion. First, the in vivo data suggest that CRIP
inds predominately to v3/5 integrins on acti-
ated myofibroblasts. It bears emphasis that v3/5
ntegrins are expressed on a variety of cell types,
ncluding macrophages, intimal and medial smooth
ells, endothelial cells of microvessels, and platelets.
lthough CRIP binding was largely confined to the
nfarct zone in the previous study by van den Borne
t al. (5), this finding may have occurred because
here was a predominance of myofibroblasts at the
ime radiolabeled CRIP was administered. Thus,
he signal-to-noise ratio of this novel molecular
maging agent may become problematic in the
linical setting, wherein the timing of infarction is
ot as well known and/or patients are being admin-
stered anti-inflammatory agents (e.g., aspirin and
tatins) that decrease inflammatory signaling, which
ight decrease the conversion of fibroblasts to
yofibroblasts. Second, it is unclear from these
tudies in which the authors used acute coronary
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201rtery occlusions whether the signal from radiola-
eled CRIP is sufficient to image myocardial fibro-
is in smaller infarcts (e.g., non–ST-segment in-
arcts) and/or myocardial fibrosis after reperfusion
njury, wherein there is an influx of inflammatory
ells that express v3/5 integrins.
Notwithstanding these potential therapeutic lim-
tations, the initial use of CRIP appears promising
n studies in patients with ischemic cardiomyopathy
14) and offers a potentially exciting new “looking
lass” for monitoring the development and progres-
ion of myocardial fibrosis during cardiac remodel-
ng. As with all things in heart failure, progress inlung structural remodelling in conges- The effect of spironeart failure therapy will require the collaborative
fforts between basic scientists and clinical scientists
o perform the requisite target validation and the
areful clinical phenotyping that are required to
ove from the bench to the bedside. To this end,
he study by van den Borne et al. (4) in the current
ssue of the Journal represents an important step.
cknowledgment
he author thanks Mary Helen Soliz for secretarial
ssistance.
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